Novel Candidates Show Promise in Turning Cold
and Refractory Tumors into Responsive Targets
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing
novel immunological agents to treat various cancers, today
announced the presentation of new data on two of its promising
investigational immunotherapy candidates, botensilimab and
AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024
Annual Meeting in Houston, Texas. The data, showcasing potential
breakthroughs in treating immune-resistant tumors, will be
presented by Dhan Chand, Ph.D., Vice President of Research at
Agenus.
The first two presentations will spotlight botensilimab, an
innovative, investigational, Fc-enhanced anti-CTLA-4 antibody that
has shown remarkable efficacy in overcoming immune barriers across
several treatment-resistant cancers, including glioblastoma,
melanoma, colorectal, pancreatic, and breast cancers.
Botensilimab’s unique mechanism of action enhances both innate and
adaptive immunity to promote optimal T-cell priming, stimulate
antigen-presenting cells, and deplete immune suppressing regulatory
T cells in the tumor microenvironment, creating a multi-pronged
attack on cold and refractory tumors.
“These findings represent a significant milestone in
understanding how botensilimab can be optimally combined with both
established and emerging therapies,” said Dr. Chand. “What’s
particularly compelling is the profound efficacy we’re seeing in
traditionally ‘cold’ tumors and treatment-resistant
cancers—offering potential new options for patients with limited
therapeutic choices.”
Featured botensilimab presentations:
Preclinical
dose-pharmacokinetic-efficacy modeling of botensilimab using a
mouse surrogate of the Fc-enhanced anti-CTLA-4 antibody
527
Location: Exhibit Halls A B
George R. Brown Convention Center
Date: Friday, Nov. 8, 2024 - Odd
Number Posters
Poster Hall Hours: 9 a.m.–7
p.m.
Fc-enhanced anti-CTLA-4 antibody,
botensilimab, enhances the efficacy of multiple therapeutic
modalities in immunotherapy-refractory tumor models
720
Location: Exhibit Halls A B
George R. Brown Convention Center
Date: Saturday, Nov. 9, 2024 -
Even Number Posters
Poster Hall Hours: 9 a.m.–8:30
p.m.
An additional presentation will cover AGEN1721, a
first-in-class, Fc-enhanced bifunctional antibody targeting FAP and
TGFβ. AGEN1721 is engineered to remodel the tumor microenvironment
by depleting cancer-associated fibroblasts (CAFs) and neutralizing
TGFβ’s immunosuppressive effects. By facilitating T-cell
infiltration and activation, AGEN1721 effectively transforms cold
tumors into "hot," immune-responsive environments.
“AGEN1721 represents a breakthrough in addressing the challenges
of immune-excluded tumors by targeting key elements that suppress
immune activity within the tumor microenvironment,” said Dr. Chand.
“The data we’re presenting at SITC 2024 highlight how AGEN1721’s
dual-action approach can dismantle barriers to immune infiltration,
offering renewed hope for more durable and effective responses
against resistant cancers.”
Featured AGEN1721 presentation:
AGEN1721, a first-in-class Fc-enhanced
bifunctional antibody targeting FAP and TGFβ, remodels the tumor
microenvironment to overcome cancer-associated fibroblast-mediated
immune suppression
1355
Location: Exhibit Halls A B George R.
Brown Convention Center
Date: Friday, Nov. 8, 2024 - Odd Number
Posters
Poster Hall Hours: 9 a.m.–7 p.m.
About Botensilimab
Botensilimab is an investigational human Fc enhanced CTLA-4
blocking antibody designed to boost both innate and adaptive
anti-tumor immune responses. Its novel design leverages mechanisms
of action to extend immunotherapy benefits to “cold” tumors which
generally respond poorly to standard of care or are refractory to
conventional PD-1/CTLA-4 therapies and investigational therapies.
Botensilimab augments immune responses across a wide range of tumor
types by priming and activating T cells, downregulating
intratumoral regulatory T cells, activating myeloid cells and
inducing long-term memory responses.
Approximately 1,100 patients have been treated with botensilimab
in phase 1 and phase 2 clinical trials. Botensilimab alone, or in
combination with Agenus’ investigational PD-1 antibody,
balstilimab, has shown clinical responses across nine metastatic,
late-line cancers. For more information about botensilimab trials,
visit www.clinicaltrials.gov with the identifiers NCT03860272,
NCT05608044, NCT05630183, and NCT05529316.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer
with a comprehensive pipeline of immunological agents. The company
was founded in 1994 with a mission to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus has robust end-to-end development
capabilities, across commercial and clinical cGMP manufacturing
facilities, research and discovery, and a global clinical
operations footprint. Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and social media channels.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding its botensilimab
and balstilimab programs, expected regulatory timelines and
filings, and any other statements containing the words "may,"
"believes," "expects," "anticipates," "hopes," "intends," "plans,"
"forecasts," "estimates," "will," “establish,” “potential,”
“superiority,” “best in class,” and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Annual Report on
Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241107623285/en/
Investors 917-362-1370 investor@agenusbio.com
Media 612-839-6748 communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Agenus (NASDAQ:AGEN)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
